Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

Y0000492

Oxycodone hydrochloride

European Pharmacopoeia (EP) Reference Standard

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C18H21NO4 · HCl
Número CAS:
124-90-3
Peso molecular:
351.82
Número MDL:
MFCD00137583
Código UNSPSC:
41116107
ID de substância PubChem:
329830982
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

oxycodone

fabricante/nome comercial

EDQM

controle de medicamentos

USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

Cl.[H][C@@]12Oc3c(OC)ccc4C[C@H]5N(C)CC[C@@]1(c34)[C@@]5(O)CCC2=O

InChI

1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

chave InChI

MUZQPDBAOYKNLO-RKXJKUSZSA-N

Informações sobre genes

human ... OPRM1(4988)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Oxycodone hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

μ and κ opioid receptor agonist.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Y0000453

Oxycodone impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000723

Thebaine, European Pharmacopoeia (EP) Reference Standard

1485191

Oxycodone, United States Pharmacopeia (USP) Reference Standard

1485216

Oxycodone Related Compound A, United States Pharmacopeia (USP) Reference Standard

1485205

Oxycodone hydrochloride, United States Pharmacopeia (USP) Reference Standard

1485238

Oxycodone Related Compound C, United States Pharmacopeia (USP) Reference Standard

1485227

Oxycodone Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP1068

Oxycodone hydrochloride, British Pharmacopoeia (BP) Reference Standard

BP1136

Oxycodone impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H302,H336

Classificações de perigo

Acute Tox. 4 Oral - STOT SE 3

Órgãos-alvo

Central nervous system

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Caitlin M Vander Weele et al.
The European journal of neuroscience, 40(7), 3041-3054 (2014-09-12)
While most drugs of abuse increase dopamine neurotransmission, rapid neurochemical measurements show that different drugs evoke distinct dopamine release patterns within the nucleus accumbens. Rapid changes in dopamine concentration following psychostimulant administration have been well studied; however, such changes have
Salvatore V Colucci et al.
Clinical drug investigation, 34(6), 421-429 (2014-04-24)
Abuse of opioid analgesics has become a public health issue. Some opioid abusers use intravenous administration to increase the magnitude of positive reinforcing effects. Intravenous co-administration of oxycodone with naloxone, an opioid antagonist, may reduce these rewarding effects and discourage
Carrie L Wade et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(2), 421-428 (2014-07-26)
The abuse of prescription opioids that are used for the treatment of chronic pain is a major public health concern, costing ∼$53.4 billion annually in lost wages, health-care costs, and criminal costs. Although opioids remain a first-line therapy for the
Jason A Miranda et al.
PloS one, 9(8), e106108-e106108 (2014-08-27)
Sensory processing in the spinal cord during disease states can reveal mechanisms for novel treatments, yet very little is known about pain processing at this level in the most commonly used animal models of articular pain. Here we report a
Tomohisa Mori et al.
Journal of pharmacological sciences, 126(1), 47-55 (2014-08-22)
The rewarding effects of μ-receptor agonists can be suppressed under several pain conditions. We recently showed that clinically used μ-receptor agonists possess efficacies for relieving the neuropathic pain induced by chemotherapeutic drug in rats; however, it is possible that the
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica